At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09995 REMEGEN
Closed 06-11 16:08:30
69.650
-0.350
-0.50%
High70.000Low66.750Vol3.16M
Open69.800D1 Closing70.000Amplitude4.64%
Mkt Cap39.26BTradable Cap14.53BTotal Shares563.61M
T/O215.67MT/O Rate1.51%Tradable Shares208.58M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
RemeGen (SEHK:9995) Valuation Check After Recent Share Price Weakness And Multi Year Gains
Simply Wall St.  ·  06-10 09:25
RemeGen (SEHK:9995) Valuation Check After Recent Share Price Weakness And Multi Year Gains
BUZZ-RemeGen Shanghai shares jump most in 10 weeks on China nod for new drug marketing
Reuters  ·  06-09 11:36
BUZZ-RemeGen Shanghai shares jump most in 10 weeks on China nod for new drug marketing
New Drug from REMEGEN Gains Approval, Boosting A and H Share Prices; Pharmaceutical ETF Rebounds, Hong Kong Stock Connect Innovative Drug ETF Maintains Premium
Deep News  ·  06-09 10:50
New Drug from REMEGEN Gains Approval, Boosting A and H Share Prices; Pharmaceutical ETF Rebounds, Hong Kong Stock Connect Innovative Drug ETF Maintains Premium
REMEGEN Shares Surge on Dual Indication Approvals for Telitacicept
Stock News  ·  06-09 10:34
REMEGEN Shares Surge on Dual Indication Approvals for Telitacicept
Movement Alert｜RemeGen Rises 5.68% in Regular Trading, Core Product Telitacicept Receives Approval for Two New Indications
Market Focus  ·  06-09 10:25
Movement Alert｜RemeGen Rises 5.68% in Regular Trading, Core Product Telitacicept Receives Approval for Two New Indications
Key Corporate Developments and Share Repurchases Highlight Hong Kong Market Activity
Stock News  ·  06-09 09:09
Key Corporate Developments and Share Repurchases Highlight Hong Kong Market Activity
RemeGen Gets Marketing Nod for Sjögren's Syndrome Drug in China
MT Newswires Live  ·  06-08 20:43
RemeGen Gets Marketing Nod for Sjögren's Syndrome Drug in China
RemeGen Secures NMPA Approval for Telitacicept’s New Indication Targeting Sjögren’s Disease
Bulletin Express  ·  06-08 20:03
RemeGen Secures NMPA Approval for Telitacicept’s New Indication Targeting Sjögren’s Disease
HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%
Tiger Newspress  ·  06-05
HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%
RemeGen Records Stable Share Base in April 2026; Public Float Fully Compliant
Bulletin Express  ·  06-04
RemeGen Records Stable Share Base in April 2026; Public Float Fully Compliant
RemeGen Maintains Stable Share Capital in May 2026, Public Float Fully Compliant
Bulletin Express  ·  06-04
RemeGen Maintains Stable Share Capital in May 2026, Public Float Fully Compliant
Stock Track | REMEGEN Plummets 5.22% Intraday as US-China Regulatory Barriers Escalate for Biotech Sector
Stock Track  ·  06-03
Stock Track | REMEGEN Plummets 5.22% Intraday as US-China Regulatory Barriers Escalate for Biotech Sector
Movement Alert｜RemeGen Falls 5.02% in Regular Trading, US-China Biotech Regulatory Barriers Escalation Pressures Innovative Drug Outbound Valuation
Market Focus  ·  06-03
Movement Alert｜RemeGen Falls 5.02% in Regular Trading, US-China Biotech Regulatory Barriers Escalation Pressures Innovative Drug Outbound Valuation
Stock Track | RemeGen Plummets 5.42% Intraday Amid US-China Biotech Regulatory Pressures
Stock Track  ·  06-02
Stock Track | RemeGen Plummets 5.42% Intraday Amid US-China Biotech Regulatory Pressures
Movement Alert｜RemeGen Intraday Decline 5.48% in Regular Trading, US-China Biotech Regulatory Escalation Continues to Pressure Innovative Pharma Sector
Market Focus  ·  06-02
Movement Alert｜RemeGen Intraday Decline 5.48% in Regular Trading, US-China Biotech Regulatory Escalation Continues to Pressure Innovative Pharma Sector
RemeGen invests RMB300.00 million in SPDB structured deposit, raising total cash-management exposure to RMB1.00 billion within two months
Bulletin Express  ·  06-01
RemeGen invests RMB300.00 million in SPDB structured deposit, raising total cash-management exposure to RMB1.00 billion within two months
REMEGEN to Deploy 300 Million Yuan of Idle Capital in Wealth Management Product from SPDB
Stock News  ·  06-01
REMEGEN to Deploy 300 Million Yuan of Idle Capital in Wealth Management Product from SPDB
Stock Track | RemeGen Plummets 5.38% Intraday Amid Escalating US-China Biotech Regulatory Tensions
Stock Track  ·  06-01
Stock Track | RemeGen Plummets 5.38% Intraday Amid Escalating US-China Biotech Regulatory Tensions
Movement Alert｜RemeGen Falls 5.08% in Regular Trading, US-China Biotech Regulatory Escalation Pressures Innovative Drug Sector
Market Focus  ·  06-01
Movement Alert｜RemeGen Falls 5.08% in Regular Trading, US-China Biotech Regulatory Escalation Pressures Innovative Drug Sector
Movement Alert｜RemeGen Rises 5.13% in Regular Trading, FDA Greenlights Telitacicept Phase II Trial for IgA Nephropathy in the US
Market Focus  ·  05-29
Movement Alert｜RemeGen Rises 5.13% in Regular Trading, FDA Greenlights Telitacicept Phase II Trial for IgA Nephropathy in the US

Introduction

Company Name.
REMEGEN
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The Company focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly operates its businesses in the domestic and overseas markets.
Issue price:
--